Home > Dermatology > Novel drug first to improve outcome of metastatic uveal melanoma

Novel drug first to improve outcome of metastatic uveal melanoma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
American Association for Cancer Research (AACR) virtual annual meeting 2021
Reuters Health - 15/04/2021 - Compared with available therapies, treatment with tebentafusp significantly improved overall survival in patients with previously untreated metastatic uveal melanoma in a phase-3 study. Uveal melanoma is a rare and aggressive form of melanoma that affects the eye. Metastatic uveal melanoma has a poor prognosis and, until now, no systemic therapy has shown a survival benefit. "Tebentafusp has the potential to be practice-changing in uveal melanoma," Dr. Jessica Hassel of the National Center for Tumor Diseases of University Hospital Heidelberg, in Germany, said at a press briefing at the American Association for Cancer Research (AACR) virtual annual meeting, where the findings were presented. Tebentafusp is a novel investigational bispecific fusion protein being developed by Immunocore, which funded the study. The protein consists of a soluble T-cell receptor (TCR) that detects HLA-A*02:01 present in the gp100 protein expressed in ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on